ReviewCancer drug resistance (Alhambra, Calif.)2023

Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment.

Kyra Laubach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.